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Impaired glucose metabolism and mitochondrial decay greatly increase with age, 27 
when cognitive decline becomes rampant. No pharmacological or dietary intervention has 28 
proven effective, but proper diet and lifestyle do postpone the onset of neurodegeneration 29 
and some nutrients are being investigated.We studied insulin signaling,mitochondrial 30 
activity and biogenesis, and synaptic signaling in the hippocampus and cortex following 31 
dietary supplementation with bioactive phospholipid concentrates of krill oil (KOC), 32 
buttermilk fat globule membranes (BMFC), and a combination of both in aged rats. After 33 
3 months of supplementation, although all groups of animals showed clear signs of 34 
peripheral insulin resistance, the combination of KOC and BMFC was able to improve 35 
peripheral insulin sensitivity. We also explored brain energy balance. Interestingly, the 36 
hippocampus of supplemented rats—mainly when supplemented with BMFC or the 37 
combination of KOC and BMFC—showed an increase in intracelular adenosine 38 
triphosphate (ATP) levels, whereas no difference was observed in the cerebral cortex. 39 
Moreover, we found a significant increase of brain-derived neurotrophic factor (BDNF) 40 
in the hippocampus of BMFC+KO animals. In summary, dietary supplementation with 41 
KOC and/or BMFC improves peripheral and central insulin resistance, suggesting that 42 
their administration could delay the onset of these phenomena. Moreover, n-3 fatty acids 43 
(FAs) ingested as phospholipids increase BDNF levels favoring an improvement in 44 
energy state within neurons and facilitating both mitochondrial and protein synthesis, 45 
which are necessary for synaptic plasticity. Thus, dietary supplementation with n-3 FAs 46 
could protect local protein synthesis and energy balance within dendrites, favoring 47 




It has been shown that insulin controls not only whole-body energy and glucose 50 
homeostasis in the periphery of the human body but also exerts specific effects in the 51 
brain (Ghasemi et al., 2013; Kleinridders et al., 2014). In fact, impaired glucose 52 
metabolism or mitochondrial dysfunction are among the major pathological changes 53 
observed in various neurodegenerative diseases (Bhat et al., 2015), which is in accordance 54 
with an increase in insulin resistance with age (Akintola and van Heemst, 2015).  55 
Insulin signaling in the brain follows the same steps described for peripheral tissues, 56 
and its receptor is expressed in neurons and glial cells in different brain regions. Among 57 
them, hippocampus and temporal cortex shows the highest levels of insulin receptor 58 
expression, indicating the important role of insulin in learning and memory (Akintola and 59 
van Heemst, 2015; Unger et al., 1991). Previous works have demonstrated that the 60 
glucose flux might regulate hippocampal memory processing through an increase of 61 
Glut4 translocation in this region (Pearson-Leary and McNay, 2016). Thus, insulin 62 
resistance in brain, due to impaired insulin receptor signaling and/or decreased insulin 63 
transport through the blood-brain-barrier, could severely affect normal cognitive 64 
processes. This becomes important when considering risk factors associated with insulin 65 
resistance, such as obesity, poor diet, physical inactivity, aging and genetic 66 
predisposition, that were further related with cognitive dysfunction and dementia 67 
(Biessels and Reagan, 2015; Bartke, 2008). Most of these factors are modifiable, 68 
indicating that prevention is crucial to avoid detrimental effects of insulin resistance. 69 
Mediterranean diet has been largely associated with lower incidence of age-related 70 
diseases, such as Alzheimer´s disease (AD). For instance, amelioration of insulin 71 
signaling was seen after treatment with hydroxytyrosol, the dominant polyphenol in extra 72 
virgin olive oil, in an astrocytic model of AD (Crespo et al., 2017b), suggesting that diet 73 
fats could play an important role at this level. Moreover, during aging, there is a constant 74 
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loss of the polyunsaturated fatty acid (PUFA) docosahexaenoic acid (DHA) in the 75 
nervous system, both in neurons and glial cells, which has been associated with 76 
pathologies such as senile dementia and AD (Jicha and Markesbery, 2010). For this 77 
reason, DHA supplementation to this risk group is of special relevance, aiming to prevent 78 
or alleviate the symptoms of these and other pathologies.  79 
FAO and WHO recommend a daily intake in adults of at least 500 mg / day EPA 80 
(eicosapentaenoic acid) + DHA (FAO et al., 2012). However, the current 81 
recommendations aim to increase the consumption of both free fatty acids (FFAs) through 82 
the intake of fatty fish, functional foods, nutraceuticals or consuming supplemented foods 83 
(Riediger et al., 2009). Regarding this, n-3 FAs associated to phospholipids are more 84 
bioavailable to different tissues, such as the brain (Wijendran et al., 2002). For this reason, 85 
krill oil is an adequate supplement, since it is rich in n-3 FAs incorporated into 86 
phosphatidylcholine (PC) and its beneficial effects have been described on blood lipids 87 
(Berge et al., 2014), inflammation (Deutsch, 2007), and even at cognitive function levels 88 
in the elderly (Konagai et al., 2013). 89 
Other source of FFAs is milk fat. The milk fat globule consists of a core, mainly 90 
composed of triacylglycerides (TAG; 98%–99%), and different concentrations of lipid 91 
compounds such as diacylglicerides, monoacylglycerides, FFAs, and cholesterol. This 92 
core is surrounded by the milk fat globule membrane (MFGM), which contains different 93 
phospho- and sphingolipids and has potential positive effects on human health, namely 94 
in neurological pathologies (Castro-Gomez et al., 2015). Buttermilk (BM), a byproduct 95 
obtained from butter manufacturing with a high content of MFGM, accounts for a 96 
significantly increased polar lipids content that may reach up to 20% of total lipid 97 
concentration (Castro-Gomez et al., 2016), which could be further increased by using 98 
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food-grade solvents to obtain BM lipids and isolate different BM fractions (Castro-99 
Gomez, 2016).  100 
One possible application of these BM fractions might be as functional food rich in 101 
phospho- and sphingolipids, along with linolenic acid, DHA and EPA precursor. 102 
Particularly, phosphatidylserine (PS) and sphingomyelin (SM) are present in this 103 
fractions, playing PS an important role in cellular functions including mitochondrial 104 
membrane integrity, release of presynaptic neurotransmitters, activity of postsynaptic 105 
receptors and activation of Protein Kinasa C in memory formation (Osella, Re et al., 106 
2008). Also, decrease of SM in myelin content in the brain has been related to the slowing 107 
in the speed of the cognitive process associated with aging (Lu, Lee et al., 2011). 108 
Due to the loss of PUFA during of aging, dietary supplementation with Butter milk 109 
fat concentrate (BMFC) and Krill oil Concentrate (KOC) could be an approach to 110 
overcome this deficit. For this reason, we aimed to study insulin signaling in hippocampus 111 
and cortex in response to dietary supplementation with bioactive phospholipids 112 
concentrates of krill oil (rich on 3-n FA and PC), BMFC (rich on linolenic acid, PS and 113 
SM) or a mix of both in aged rats. Mitochondrial activity and biogenesis, and synaptic 114 
signaling were also assessed. 115 
 116 
Materials and methods 117 
Materials 118 
Buttermilk and krill oil concentrates (BMFC and KOC, respectively) and the 119 
elaboration of daily doses in the form of a jelly lollipop were produced at the Institute of 120 
Food Science Research (CIAL, Madrid, Spain). Briefly,BM fat was extracted by 121 
pressurized liquid extraction (PLE) using an accelerated solid ASE-200 extractor (Dionex 122 
Corp. Sunnyvale, CA). Fifteen grams of powdered BMwere mixed with sand (1:1, by 123 
weight) and loaded into a stainless steel extraction cell. To obtain the maximum BMfat 124 
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yield, the extraction procedure was based on the optimized PLE method of Castro-Gomez 125 
et al. 2014. The lipid extracts were capped under nitrogen and stored at − 35 °C. 126 
Animals 127 
This research project followed the Guide for the Care and Use of Laboratory Animals, 128 
published by the US National Research Council (Eight Edition, 2010). Animal care was 129 
according to the standards proposed by the European Community (86/609/EEC). Animal 130 
experiments were approved by the Animal Experimentation Committee of the National 131 
University of Distance Education. A total of 41 male Wistar rats (9 months of age) were 132 
purchased from Charles River Laboratories (Barcelona, Spain). Rats were distributed 133 
randomly in groups of two per box and maintained in a 12:12 light-dark cycle (8 a.m. to 134 
8 p.m.), with constant temperature and humidity conditions (22 ± 2° C and 50% RH), 135 
during the following 9 months. Food and water were given ad libitum. 136 
Experimental design and diets 137 
Since 18-months’ rats are considered old and present a variety of cognitive deficiency 138 
(CD) symptoms associated with aging, when animals reached this age they were 139 
randomly assigned to four experimental groups (Table 1). All groups were given a 140 
standard diet EURodent (LabDiet, San Luis, Misuri) plus a group-specific supplement 141 
intake in form of frozen strawberry jellies: 1) control group - refined olive oil, 2) BMFC 142 
group – concentrate of phospholipids from dairy fat globule membrane, 3) KOC group - 143 
concentrate of krill oil (KO) omega-3 fatty acids (eicosapentaenoic acid (EPA), 144 
and docosahexaenoic acid (DHA)) enriched phospholipids, and 4) BMFC + KOC group 145 
– one identical jelly containing  the same treatment from group 2 and group 3 given 146 
simultaneously. Detailed composition of different lipid classes is described in Table 2. 147 




The nutritional composition of the daily diet of the four experimental groups is shown 150 
in Table 3. Rats were sacrificed by decapitation after three months of supplementation, 151 
following a 12-hour fast. Hippocampus and temporal cortex were quickly extracted, 152 
washed in PBS, snap-frozen in liquid nitrogen, and stored at -80 ˚C. Blood samples were 153 
collected with heparin (100UI/mL), centrifuged for plasma collection at 1500 xg for 15 154 
minutes and stored at -80 ºC until used. 155 
Determination of circulating biochemical parameters. 156 
Concentration of plasma glucose was measured with commercial kits (WAKO, Neuss, 157 
Germany) and insulin levels were determined by an ELISA kit (Rat Insulin, 96-well plate 158 
assay, Millipore, Madrid, Spain), according to the manufacturer’s instructions. The index 159 
of insulin resistance, a.k.a. homeostasis model assessment ratio (HOMA-R), was 160 
calculated using the following formula:   161 
HOMA= fasting glucose (mmol/L)×fasting insulin (μIU/mL)/22.5.  162 
Measurement of ATP levels in tissue samples 163 
To evaluate the energy status of the cells in the hippocampus and temporal cortex, a 164 
bioluminescent assay was used to assess intracellular adenosine triphosphate (ATP) levels 165 
(Sigma- Aldrich, St Lois MO, USA). The homogenized samples were previously filtered 166 
through 0.22 pm filters (Millipore Corp., Bedford, Mass.). The kit was performed 167 
according to the manufacturer’s protocol and luminescence was measured using a 168 
microplate reader at 570 nm (Biochrom Asys UVM 340, Cambridge, UK). 169 
RNA isolation and qRT-PCR 170 
Total RNA extraction from both tissues were performed according to the 171 
manufacturer’s instructions for the miRNeasy Mini kit (Qiagen, Madrid, Spain), 172 
including DNA digestion. RNA quantity and purity were analysed using a NanoDrop ND-173 
1000 UV-Vis Spectrophotometer (Thermo Fisher Scientific Inc., Spain) and RNA 174 
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integrity using an Agilent's 2100 bioanalyser. Total RNA was converted into first strand 175 
cDNA using miScript®II Reverse Transcription kit, Qiagen (Izasa, Barcelona, Spain) 176 
according to the manufacturer’s guidelines.  177 
Electron transport chain array 178 
A Mitochondria energy metabolism (SAB Target List) H384 Predesigned 384-well 179 
panel (Bio-Rad, Madrid, Spain) was carried out. Five samples of each experimental group 180 
with the highest RINs were selected to perform the assay. The pre-designed plates were 181 
formed by 87 genes, within these 10 are reference genes, 27 genes belong to complex I; 182 
4 to complex II, 6 to complex III, 15 to complex IV, 18 to complex V, and 7 are associated 183 
with the respiratory chain, although they are not included in any complex. 184 
qRT-PCR reactions were performed using miScript SYBR Green PCR Kit from 185 
Qiagen (Izasa, Madrid, Spain) using a 7900HT Real-Time PCR System (Life 186 
Technologies, Alcobendas, Spain). Cycling conditions were a first step of activation at 187 
95 °C for 15 minutes; 40 cycles of denaturation at 94 °C for 15 seconds, annealing at 58 188 
°C for 30 seconds and a final step for dissociation curve. PPA1 was identified by 189 
NormFinder as the most stable reference gene among 10 other candidates.  190 
Determination of synaptoproteins gene expression. 191 
Gene expression analysis of genes encoding proteins involved in the nerve synapses 192 
were performed by qRT-PCR (see above) in a 384-well plate using ABI PRISM 7900HT 193 
real-time PCR system. Cycling conditions were the same as describe above. Specific 194 
primers for each gene were designed using Primer3 software (Supplementary Table 1). 195 
Quantification of relative gene expression was performed using the comparative delta Ct 196 
method using GAPDH as reference genes for normalization. 197 
Western blot assays 198 
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Temporal cortex and hippocampus samples were homogenized with RIPA lysis buffer 199 
containing protease and phosphatase inhibitors (Sigma-Aldrich, Madrid, Spain). 200 
Homogenates were kept at -80°C for 24 h, centrifuged (4 °C, 12000 xg, 30 min) and 201 
supernatants were collected. Total protein concentrations were determined using BCA 202 
protein assay reagent (ThermoFisher Scientific, Madrid, Spain). Equal amounts of protein 203 
(30 μg) were electrophoresed on 10% sodium dodecyl sulfate-polyacrylamide gel 204 
electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (Bio-Rad, 205 
Madrid, Spain). Membranes were blocked with 5% non-fat milk powder in Tris-buffered 206 
saline containing 0.1% Tween-20 (TBS-T) for 2 h at room temperature, and then 207 
incubated overnight at 4 °C with various primary antibodies regarding key components 208 
of the insulin signaling pathway, components of the neurotransmissions and 209 
neurodegenerations (Supplementary Table 2) and involved in respiratory 210 
mithochondrial chain (abcam ab110413). Following incubation with appropriate 211 
secondary antibodies protein bands were detected by an enhanced chemiluminescence 212 
method using the ECL kit (Bio-Rad, Madrid, Spain). Normalization of total protein 213 
expression was carried out using GAPDH or with their corresponding total form in the 214 
case of phosphorylated proteins.  215 
Statistical analysis 216 
Statistical analyses were carried out using GradPad Prism 7.02 software (GraphPad 217 
Software, Inc., La Jolla, CA, USA). For the gene expression analysis, data was quantified 218 
using the ΔΔCt method and fold-change values were reported as 2−(ΔΔCt). Data from 219 
independent samples from all experiments was compared by one-way ANOVA using 220 
Tuckey test to compare all study groups.  Values of p < 0.05 was considered significant. 221 
Results are presented as means ± SEM. 222 




Combination of BMFC and KOC improves peripheral insulin sensitivity 225 
Aged rats fed with isocaloric diets (Table 1) during 3 months did not show any 226 
apparent changes in body weight (data not shown). Since insulin resistance is tightly 227 
associated to aging and cognitive dysfunction (Umegaki et al., 2017), we wondered 228 
whether different dietary supplements affected glycemic profiles. No significant 229 
differences in glucose levels in any of the study groups were observed (Figure 1A). 230 
However, glucose levels in all groups indicated that there is an insulin resistance process, 231 
since the normal physiological glucose range is around 75.4 ± 5.5 mg/ml in adults rats 232 
(from 4 months) (Burgos-Ramos et al., 2011). Indeed, the studied aged rats presented 233 
values closed to 150 mg/dl. Along with this, serum insulin concentrations were higher 234 
than in adult rats. Compared to the control group, the combination of BMFC with KOC 235 
reached lower insulin levels (Figure 1B). This observation was further confirmed by the 236 
HOMA ratio (Figure 1C), suggesting that the mixture improves peripheral insulin 237 
sensitivity.  238 
Hippocampal and cortical insulin signaling is increased in high phospholipid 239 
concentrate diets  240 
Dysregulation of brain insulin signaling has been linked to aging and neurodegenerative 241 
disorders (Biessels and Reagan, 2015; Ghasemi et al., 2013; Kleinridders et al., 2014). To 242 
determine whether the different supplements influence central insulin signaling, we next 243 
evaluated key insulin pathway molecules in hippocampus and cerebral cortex. Protein 244 
analysis from hippocampal samples showed a significant increase in the insulin receptor 245 
subunit IRβ expression levels both in KOC and BMFC+KOC (Figure 2A), whereas the 246 
activated insulin substrate IRS1 was augmented in those groups supplement with BMFC. 247 
This activation mediated by insulin receptor was not observed in the IRS2 protein. Since 248 
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cytoplasmic insulin signaling is mediated through PI3K, we also explored the expression 249 
levels of the regulatory subunit p85 from this kinase. As seen for IRS1, BMFC 250 
supplementation rose PI3K expression levels. Since the last step of the insulin pathway, 251 
Akt activation, was detected in hippocampal samples of the three experimental groups, it 252 
seems possible that a high phospholipid diet improves hippocampal insulin signaling. 253 
Moreover, cerebral cortex insulin signal analysis showed that this route was also activated 254 
in this area (Figure 2B), suggesting that this effect is not only restricted to one brain 255 
region. 256 
Activation of the insulin intracellular signaling stimulates the translocation of the 257 
Glut4 transporter facilitating glucose uptake (Biessels and Reagan, 2015). Thus, we 258 
examined transporter levels in our samples (Figure 2A and B). However, we did not find 259 
significant differences in Glut4 levels in any of the supplemented groups. 260 
BMFC+KOC Ameliorate Cellular Energy States and Increase Mitochondrial 261 
Biogenesis in Hippocampus  262 
Energetic state levels in brain tissue are influenced by mitochondrial biogenesis, 263 
which can be dramatically damaged during aging. Thus, we first evaluated the 264 
intracellular levels of adenosine triphosphate (ATP) in hippocampal samples. We found 265 
that all experimental groups showed an increase in ATP levels, being significant in BMFC 266 
animals (Figure 3A). Interestingly, this improvement was not detected in cerebral cortex 267 
samples (Figure 3B), suggesting that supplementation with bioactive phospholipids 268 
differently affects brain areas at this level. Thus, we wanted to figure out whether this 269 
increased energetic state in hippocampus could be due to an augmented mitochondrial 270 
biogenesis. To achieve this, we carried out protein analysis expression of the five 271 
complexes (Figure 3C). Animals fed with both BMFC and KOC supplement increased 272 
the expression of proteins from all the complexes studied, suggesting that amelioration of 273 
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cell energy state is mediated by an increase in mitochondrial biogenesis. We also 274 
evaluated the expression of 70 genes corresponding to the five mitochondrial complexes 275 
and seven associated with the respiratory chain (not included in any complex) in the 276 
hippocampus. An increase in the expression of key genes involved in the complexes I, 277 
IV, and V (Fig. 3d) was detected by qRT-PCR, confirming the observed changes in 278 
protein levels. 279 
 280 
Mitochondrial biogenesis in BMFC+KOC animals is mediated through BDNF 281 
In order to determine whether the increased levels in mitochondrial complex proteins 282 
were mediated by the regulator of mitochondrial biogenesis, the peroxisome proliferator-283 
activated receptor  coactivator 1-α (PGC-1α), we explored the levels of this protein in 284 
hippocampal and cortical samples (Figure 4A and 4B). As seen is Figure 4A and 4B, 285 
PGC1-α was increased in BMFC+KOC rats in both brain areas. Since, this coactivator is 286 
regulated by the master metabolic regulator 5’ AMP-activated protein kinase (AMPK), 287 
we further explored the levels of this kinase along with the NAD+-dependent type III 288 
deacetylase SIRT1 (Canto et al., 2009). Strikingly, although phosphorylated levels of 289 
AMPK were only increased in the KOC group both in hippocampus and cerebral cortex, 290 
SIRT1 levels were decreased in all experimental groups in the hippocampus and a trend 291 
(not significant) was observed in the cortex. As it has been described that PGC-1α 292 
activation requires both AMPK and SIRT1 (Canto et al., 2009), our results suggest that 293 
AMPK-SIRT1-mediated PGC1-α regulation is not taking place in our model.  294 
Brain-derived neurotrophic factor (BDNF) has been implicated in neural ATP 295 
enhancement and in PGC-1α activation (Marosi and Mattson, 2014a). Thus, we next 296 
analyzed BDNF levels in hippocampal samples (Figure 4A). Only BMFC+KOC 297 
supplemented animals showed an increase in BDNF levels, in accordance with the results 298 
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for PGC-1α. However, although cortical BDNF was increased in all treated group, in this 299 
brain area it did not reach significant levels. This suggest that the incremented of 300 
mitochondrial biogenesis observed in hippocampus of BMFC+KOC rats could be 301 
mediated by BDNF. It has been proposed that BDNF exerts its actions through the 302 
mammalian target of rapamycin (mTOR), favoring local protein synthesis in dendrites 303 
(Takei et al., 2004). Thus, we examined mTOR levels in hippocampal and cortical 304 
samples. Increased levels of mTOR activity were detected in rats supplemented with 305 
BMFC+KOC, indicating that improvement in hippocampal energy state was mediated by 306 
mTOR through BDNF. 307 
 308 
Synaptic proteins are differently regulated in distinct brain areas 309 
Since mitochondrial biogenesis is necessary for BDNF to stimulate the formation of 310 
new synapses and to maintain the existing ones (Marosi and Mattson, 2014a), we wonder 311 
whether the observed changes in energy status after supplement treatment can be linked 312 
to synaptic signaling. Thus, we first analyzed the expression levels of genes encoding pre- 313 
and postsynaptic proteins in hippocampal samples (Figure 5A). Interestingly, syntaxin 314 
1A gene levels (Stx1A) were highly augmented in BMFC+KOC animals, whereas 315 
synapsin I (Syn1) and synaptotagmin 1 (Syt1) were not changed after the different 316 
treatments. We further examined postsynaptic structural proteins PDS95, PDS93 and 317 
SAP-102 levels (Dlg4, Dlg2 and Dlg3, respectively) and found that, surprisingly, while 318 
Dlg4 levels were increased in KOC rats, expression of the three genes were decreased in 319 
the BMFC+KOC group. In order to confirm these results, we developed western blots for 320 
the plasma membrane protein Stx1A and two other presynaptic proteins associated with 321 
synaptic vesicles, synaptobrevin 2 (Vamp2) and the chaperone α-synuclein (α-Syn) 322 
(Figure 5B). Although Stx1A mRNA levels was increased in the BMFC+KOC animals, 323 
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protein levels were not changed in any of the experimental groups. Only Vamp-2 was 324 
increased in all supplemented animals.  325 
In the case of cerebral cortex samples, gene expression of the pre- and postsynaptic 326 
proteins showed increased levels in some of them (Figure 5C). Stx1A levels were 327 
significantly increased in BMFC+KOC rats, whereas Syt1 mRNA was upregulated in all 328 
studied groups compared to that of control animals. At protein level (Figure 5D), Stx1a 329 
and α-Syn was icreased in KOC group and only α-Syn was augmented in BMFC group. 330 
These results highlight different synaptic regulation in distinct brain areas.  331 
 332 
Discussion 333 
There is growing evidence that cognitive decline associated to aging can be 334 
partially prevented through the change of certain lifestyle factors, such as diet and regular 335 
exercise (Fontana et al., 2014; Daviglus et al., 2011). In fact, Mediterranean diet has been 336 
related with lower incidence of age-related diseases, such as AD and cardiovascular 337 
disease (Jackson et al., 2016; Estruch et al., 2013). Thus, dietary fats, such as those from 338 
olive oil, could act as key players in aging effects, ameliorating, for instance, insulin 339 
signalling in brain (Crespo et al., 2017a). Moreover, diet supplementation with PUFA, 340 
such as DHA, or the more available n-3 FAs associated to phospholipids, such as krill oil, 341 
could be a good approach in order to prevent aging (Wijendran et al., 2002; Konagai et 342 
al., 2013). Although milk fat globule membranes supplementation in infant and children  343 
seems to have certain neurodevelopment benefits (Hernell et al., 2016), their effects on 344 
the elderly is poorly characterized (Kim et al., 2015; Minegishi et al., 2016). 345 
 346 
As insulin resistance has been largely related with age and its associated diseases 347 
(Akintola and van Heemst, 2015), we aimed to study brain insulin signaling in response 348 
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to dietary supplementation with bioactive phospholipids concentrates of krill oil and 349 
butter milk in aged rats. After three months of supplementation, although all groups of 350 
animals showed clear signs of peripheral insulin resistance, only the combination of KOC 351 
and BMFC was able to improve peripheral insulin sensitivity. In fact, both krill oil and 352 
MFGM have been previously shown to reduce insulin levels in type 2 diabetes and obese 353 
individuals, respectively (Lobraico et al., 2015; Demmer et al., 2016), suggesting that 354 
dietary FFA/phospholipids could help at this level. In order to know whether this 355 
amelioration in peripheral insulin resistance could also be detected at central nervous 356 
system level, we further explored insulin signaling in hippocampus and cerebral cortex, 357 
both brain areas implicated in cognitive processes. Interestingly, insulin signaling was 358 
improved in both structures, since the cascade of events was active when animals were 359 
supplemented with BMFC, KOC or both. These results highlight the importance of 360 
dietary fats in the compensation of disturbed insulin pathway observed in aging.  361 
 362 
Considering that the energetic state level in brain is influenced by its mitochondrial 363 
content, we further explored brain energy balance. Interestingly, the hippocampus of 364 
supplemented rats—mainly with BMFC or the combination of KOC and BMFC—365 
showed an increase in ATP levels, whereas no difference was observed in the cerebral 366 
cortex, suggesting that dietary fats induce different energy states in distinct brain areas, 367 
which is coherent with the observation that n-3 fatty acids incorporate into the various 368 
brain structures in a non-random, selected fashion (Lamaziere et al, 2011). The increased 369 
energy status of the hippocampus might be due to an increase in mitochondrial 370 
biogenesis, because both mitochondrial complexproteins and PGC-1α, the key regulator 371 
of mitochondrial biogenesis, were augmented in BMFC+KOC-supplemented animals. 372 
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Remarkably, although we did not record higher ATP levels in the cerebral cortex of 373 
supplemented animals, BMFC+KOC rats presented increased levels of PGC-1α, 374 
suggesting that the combination of the two types of fat favors the increase of this 375 
transcription factor, in turn indicating an increase in mitochondrial biogenesis signaling 376 
in this brain area. Since all treated animals presented increased levels of the 377 
neurotrophin BDNF, upregulation of PGC-1α appears to be mediated through it rather 378 
than AMPK-SIRT1. However, we only found a significant increase of BDNF in the 379 
hippocampus of BMFC+KOC animals. It is noteworthy that cerebral 380 
BDNF levels are quite low (Marosi and Mattson, 2014) and perhaps even a slight rise in 381 
BDNF levels could promote the action of PGC-1α in the cerebral cortex. 382 
BDNF stimulates mitochondrial biogenesis to form new synapses and to maintain the 383 
existing ones (Marosi and Mattson, 2014b). In fact, local protein synthesis at dendrite 384 
level is crucial in order to sustain synaptic plasticity, being BDNF the main modulator 385 
(Takei et al., 2004). Thus, BDNF facilitates synaptogenesis inducing mTOR pathway, 386 
which mediates signals for local protein synthesis (Takei et al., 2004). According to our 387 
previous results, in hippocampus, combined supplementation with both KOC and BMFC 388 
favored mTOR activation. Thus, animals fed with both fats presented all the necessary 389 
steps for synapse formation (Takei et al., 2004).  390 
Although our results point to an improvement in synaptogenesis in hippocampal 391 
samples of BMFC+KOC-supplemented animals, when we explored synaptic genes and 392 
proteins, we did not find significant increases in this brain area. Surprisingly, cerebral 393 
cortices presented an induction of synaptic protein synthesis in all supplemented groups, 394 
although the highest levels were detected in the BMFC+KOC-supplemented group. As 395 
mentioned above, although BDNF and mTOR levels increased, statistical significance 396 
was not seen regarding controls, but it may be possible that such increase is enough to 397 
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improve synaptic protein synthesis at the dendrite level. 398 
In summary, dietary supplementation with KOC and/or BMFC has improved 399 
peripheral and central insulin resistance, suggesting that they could be a good approach 400 
to delay this process. Moreover, n-3 fatty acids ingested as phospholipids ameliorate 401 
BDNF brain levels, as described before (Wu et al., 2004), favoring an improvement in 402 
energy state within neurons and facilitating both mitochondrial and protein synthesis, 403 
which are necessary for synaptic plasticity. Thus, dietary supplementation with n-3 FAs 404 
could protect local protein synthesis and energy balance within dendrites, favoring 405 
neuronal health and delaying cognitive decline associated to age-related diseases.  406 
 407 
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Figure Legend  426 
 427 
Figure 1.  Determination of insulin, glucose and insulin resistance index in rat serum. 428 
Control: control group; BMFC: Concentrate of bioactive phospholipids from dairy fat 429 
globule membrane; KOC: concentrate of omega-3 fatty acids (Eicosapentaenoic acid 430 
(EPA) and docosahexaenoic acid (DHA)) enriched in phospholipids from krill oil; 431 
BMFC+KOC: Mixing of the two bioactive phospholipid concentrates. A) Glucose levels 432 
expressed in mg/mL. B) Insulin levels expressed in mg/mL. C) homeostasis model 433 
assessment ratio (HOMA-R), which is an index of insulin resistance. Values are 434 
expressed as mean ± SEM of the mean. *Statistically significant difference regarding all 435 




Figure 2.  Western blot of proteins involved in the insulin-signaling pathway. A) 438 
Hippocampus samples B) Temporal cortex samples. IRβ: Insulin receptor; pIRS1: 439 
Phosphorylated insulin receptor substrate 1; IRS1: Insulin receptor substrate 1; IRS2: 440 
Insulin receptor substrate 2;  p85: Subunit of phosphatidylinositol 3-kinase(PI3K); AKT: 441 
Serine/threonine protein kinase; pAKT 308: Phosphorylated AKT threonine 308; pAKT 442 
473: Phosphorylated AKT serine 473; GLUT4: Glucose transporter 4; Control: Control 443 
group; BMFC: Concentrate of bioactive phospholipids from dairy fat globule membrane; 444 
KOC: concentrate of omega-3 fatty acids (Eicosapentaenoic acid (EPA) and 445 
docosahexaenoic acid (DHA) enriched in phospholipids from krill oil; BMFC+KOC: 446 
Mixing of the two bioactive phospholipid concentrates. Values are expressed as mean ± 447 
SEM of the mean. Statistically significant difference regarding all study groups at 448 
* p <0.05-0.005;** p <0.005-0,0005; *** p <0.0005. 449 
 450 
Figure 3. Measurement of cellular energy status and mitochondrial biogenesis. A & B) 451 
ATP levels expressed in pmol/µl. C) Western blots analysis involved in respiratory 452 
mitochondrial chain in hippocampus.  D) Gene expression involved in mitochondrial 453 
respiratory chain pathway performed on hippocampus samples. ATP: adenosine 454 
triphosphate; Ndufab1:NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1; 455 
Slc25a10: solute carrier family 25 (mitochondrial carrier, dicarboxylate transporter), 456 
member 10; Atp5h:ATP synthase, H+ transporting, mitochondrial F0 complex, subunit 457 
D; Atp4a: ATPase H+/K+ transporting alpha subunit; Cox8c: cytochrome c oxidase 458 
subunit 8C; Atp4b:ATPase H+/K+ transporting beta subunit ; Cox17:cytochrome c 459 
oxidase copper chaperone; Uqcrb: ubiquinol-cytochrome c reductase binding protein; CI: 460 
Complex I; NC: does not belong to any complex; CIV: Complex IV; CV: Complex V; 461 
Control: control group; BMFC: Concentrate of bioactive phospholipids from dairy fat 462 
globule membrane; KOC: concentrate of omega-3 fatty acids (Eicosapentaenoic acid 463 
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(EPA) and docosahexaenoic acid (DHA) enriched in phospholipids from krill oil; 464 
BMFC+KOC: Mixing of the two bioactive phospholipid concentrates. Values are 465 
expressed as mean ± SEM of the mean. Statistically significant difference regarding all 466 
study groups at * p <0.05-0.005;** p <0.005-0,0005; *** p <0.0005. 467 
 468 
Figure 4. Western blot of proteins involved in mitochondrial biogenesis. A) 469 
Hippocampus samples B) Temporal cortex samples. PGC1: Peroxisome proliferative 470 
activated receptor, gamma, coactivador 1 alpha; pAMPK: phosphorylated AMPK; 471 
AMPK: AMP-activated protein kinase; SIRT1: Sirtuin 1; BDNF: brain derived 472 
neurotrophic factor; pmTOR: phosphorylated mechanistic target of rapamycin kinase; 473 
mTOR: mechanistic target of rapamycin kinase; Control: control group; BMFC: 474 
Concentrate of bioactive phospholipids from dairy fat globule membrane; KOC: 475 
concentrate of omega-3 fatty acids (Eicosapentanoic acid (EPA) and docosahexaenoic 476 
acid (DHA)) enriched in phospholipids from krill oil; BMFC+KOC: Mixing of the two 477 
bioactive phospholipid concentrates. Values are expressed as mean ± SEM of the mean. 478 
Statistically significant difference regarding all study groups at * p <0.05-0.005; ** 479 




Figure 5. Synaptic-proteins expression in both tissues. A) Expression analysis of genes 482 
encoding proteins involved in the nerve synapse in hippocampus. B) Hippocampus 483 
Western blot of proteins involved in the neurotransmission signaling. C) Expression 484 
analysis of genes encoding proteins involved in the nerve synapse in Temporal cortex 485 
samples. D) Temporal Western blot of proteins involved in the neurotransmission 486 
signaling. STX1A: syntaxin 1A; SYN: synapsin I; SYT1: synaptotagmin 1; Dlg4: discs 487 
large MAGUK scaffold protein 4 (PSD95); Dlg2: discs large MAGUK scaffold protein 488 
2 (PSD93); Dlg3: discs large MAGUK scaffold protein 3 (SAP-102); Vamp-2: vesicle-489 
associated membrane protein 2; α-Syn: synuclein alpha; Control: control group; BMFC: 490 
Concentrate of bioactive phospholipids from dairy fat globule membrane; KOC: 491 
concentrate of omega-3 fatty acids (Eicosapantaenoic acid (EPA) and docosahexaenoic 492 
(DHA)) enriched in phospholipids from krill oil; BMFC+KOC: Mixing of the two 493 
bioactive phospholipid concentrates. Values are expressed as mean ± SEM of the mean. 494 
Statistically significant difference regarding all study groups at * p <0.05-0.005; ** 495 
p <0.005-0,0005; *** p <0.0005. 496 
 497 
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Table 1. Experimental design of the study. 604 
Experimental Group Control diet Daily supplement (jelly) 
Control ad libitum 70 mg refined olive oil 
BMFC ad libitum 70 mg of BMFC 
KOC ad libitum 70 mg of KOC 
BMFC+KOC ad libitum 70 mg of BMFC + 70 mg of KOC 
Control: Control group; BMFC: Concentrate of bioactive phospholipids from dairy fat 605 
globule membrane; KOC: concentrate of omega-3 fatty acids (Eicosapentaenoic acid 606 
(EPA) and docosahexaenoic acid (DHA)) enriched in phospholipids from krill oil; 607 
BMFC+KOC: Mixing of the two bioactive phospholipid concentrates. 608 
 609 
Table 2. Composition of lipidic classes of concentrates used to formulate the different 610 
experimental diets. 611 
 
 Control BMFC KOC BMFC + 
KOC 
PE (%) - 0.55 15.66 5.16 
PI (%) - - 1.92 0.77 
PS (%)  - - 16.92 6.79 
PC (%) - 99.45 38.74 72.48 
SM (%) - - 26.76 14.79 
 612 
Control: control group; BMFC: Concentrate of bioactive phospholipids from dairy fat 613 
globule membrane; KOC: concentrate of omega-3 fatty acids (Eicosapentaenoic acid 614 
(EPA) and docosahexaenoic acid (DHA)) enriched in phospholipids from krill oil; 615 
BMFC+KOC: Mixing of the two bioactive phospholipid concentrates. %: Percentage of 616 
different phospholipids; PE: phosphatidylethanolamine; PI: phosphatidylinositol; PS: 617 
phosphatidylserine; PC: phosphatidylcholine; SM: sphingomyelin. 618 
 619 
 Table 3. Nutritional composition of the daily diet of the five experimental groups. 620 
 
 Control BMFC KOC BMFC + 
KOC 
Energy (Kcal) 201,07 201,11 201,07 201,75 
Lipids (g) 1,82 1,82 1,82 1,89 
Carbohydrates (g)  32,10 32,11 32,10 32,11 
Fiber (g) 2,05 2,05 2,05 2,05 
Proteins (g) 11,01 11,01 11,01 11,01 
 621 
Control: control group; BMFC: Concentrate of bioactive phospholipids from dairy fat 622 
globule membrane; KOC: concentrate of omega-3 fatty acids (Eicosapentaenoic acid 623 
(EPA) and docosahexaenoic acid (DHA)) enriched in phospholipids from krill oil; 624 
BMFC+KOC: Mixing of the two bioactive phospholipid concentrates. 625 
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Supplemental information (SI) 626 
 627 
Supplemental Table S1. Sequence of synapto-proteins primers analyzed 628 







F: 5′- GCCCTGTTTGATTACGACAA-3′ 
R: 5′- ACTCGGTTCTGAGCTATGAG  
 
Syn1 
F: 5′- TGTCCCGAAAGTTTGTG-3′ 
R: 5′- GCGTTCTCGGTAGTCT 
 
Syt1 
F: 5′- CTTCTCCAAGCACGACATCA-3′ 







F: 5′- TAGGGCCCTGTTTGATTACG-3′ 
R: 5′- TGGCCTTTAACCTTGACCAC -3′ 
 
Dlg3 
F: 5′- GAGTTCCCGCATAAGTTTGG-3 
R: 5′- CGGACACGTCTAAGATGCAG -3′ 
 
Dlg2 
F: 5′- GTCGGAGGTTTCCCACAGTA-3′   
R: 5′- CTGTGCAGCTCCACCATCTA -3′  
Stx1A: syntaxin 1A; Syn: synapsin I; Syt1: synaptotagmin 1; Dlg4: discs large MAGUK scaffold protein 629 
4; Dlg2: discs large MAGUK scaffold protein 2; Dlg3: discs large MAGUK scaffold protein 3; F: 630 
Forward; R: Reverse.  631 
 632 
Supplemental Table 2. List of primary antibodies used to analyze the insulin signaling 633 






60 Rabbit Cell Signaling * 
p-thr473-
AKT 
60 Rabbit Cell Signaling * 
AKT 60 Rabbit Cell Signaling * 
p-mTOR 289 Rabbit Cell Signaling * 
mTOR 289 Rabbit Cell Signaling * 
p-IRS1 90 Rabbit Santa Cruz Biotechnology ** 
IRS1 90 Rabbit Santa Cruz Biotechnology ** 
IRS2 185 Mouse Millipore * 
IRβ 75-100 Mouse Santa Cruz Biotechnology ** 
p85 PI3K 75-85 Mouse Santa Cruz Biotechnology ** 
p-AMPK 
α1/2 
60 Rabbit Santa Cruz Biotechnology ** 
AMPK α1/2 63 Mouse Santa Cruz Biotechnology ** 
SIRT1 120 Rabbit Santa Cruz Biotechnology ** 
PGC1 90 Rabbit Santa Cruz Biotechnology ** 
GLUT2 55-60 Rabbit AD Internacional *** 
GLUT4 50-63 Mouse Santa Cruz Biotechnology ** 
VAMP-2 18 Mouse Santa Cruz Biotechnology ** 
Syntaxin 1 35 Mouse Santa Cruz Biotechnology ** 
p-TAU 50-80 Mouse Cell Signaling * 
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TAU-5 46-80 Mouse Santa Cruz Biotechnology ** 
α-synuclein  19 Mouse Santa Cruz Biotechnology ** 
BDNF 14 Mouse Novusbio **** 
UBB 9 Mouse Millipore * 
*(Madrid, Spain); **(Heidelberg, Germany); ***(San Antonio, USA); ****(Abingdon, 635 
United Kingdom) Leyenda anticuerpos 636 
 637 
